Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect in Patients with Traumatic Brain Injury: PRISM-II.

A multicenter, open label study (PRISM-II) was conducted to assess effectiveness, safety, and tolerability of dextromethorphan and quinidine (DM/Q) combination for the treatment of pseudobulbar affect (PBA) in patients with stroke, dementia, or traumatic brain injury (TBI). Enrollment has now completed for the cohort of patients with PBA secondary to dementia (results already reported), stroke, and TBI; results for the TBI cohort will be presented.

http://www.archives-pmr.org/article/S0003-9993(15)00665-6/abstract?rss=yes

Source: Archives of Physical Medicine and Rehabilitation - October 1, 2015 Category: Rehabilitation Authors: Flora Hammond, William Sauve, Paul Shin, Fred Ledon, Charles S. Davis, Charles Yonan, Joao Siffert Tags: Oral presentation Source Type: research